Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Retained Earnings: 2020-2024

Historic Retained Earnings for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to -$1.7 billion.

  • Relay Therapeutics' Retained Earnings fell 17.65% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 17.65%. This contributed to the annual value of -$1.7 billion for FY2024, which is 24.11% down from last year.
  • Relay Therapeutics' Retained Earnings amounted to -$1.7 billion in FY2024, which was down 24.11% from -$1.4 billion recorded in FY2023.
  • Over the past 5 years, Relay Therapeutics' Retained Earnings peaked at -$404.2 million during FY2020, and registered a low of -$1.7 billion during FY2024.
  • For the 3-year period, Relay Therapeutics' Retained Earnings averaged around -$1.4 billion, with its median value being -$1.4 billion (2023).
  • Data for Relay Therapeutics' Retained Earnings shows a maximum YoY tumbled of 90.02% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Relay Therapeutics' Retained Earnings stood at -$404.2 million in 2020, then tumbled by 90.02% to -$768.1 million in 2021, then tumbled by 37.82% to -$1.1 billion in 2022, then crashed by 32.30% to -$1.4 billion in 2023, then fell by 24.11% to -$1.7 billion in 2024.